Glaukos (NYSE:GKOS) CFO Sells 15,000 Shares of Company Stock

Glaukos Corporation (NYSE:GKOS – Get Free Report) CFO Alex Thurman sold 15,000 shares of the business’s stock in a transaction on Wednesday, November 18th. The shares were sold at an average price of $236.92, for a total value of $3,553,800.00. Following the completion of the sale, the chief financial officer directly owned 43,906 shares in the company, valued at approximately $10,402,209.52. This represents a 25.46% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Glaukos Price Performance

NYSE:GKOS traded down $0.86 during trading hours on Friday, reaching $237.24. The company had a trading volume of 1,089,557 shares, compared to its average volume of 964,002. The stock has a 50-day moving average of $189.52 and a two-hundred day moving average of $149.49. Glaukos Corporation has a one year low of $93.78 and a one year high of $255.18. The firm has a market capitalization of $14.04 billion, a PE ratio of -80.69 and a beta of 0.68. The company has a quick ratio of 4.09, a current ratio of 4.57 and a debt-to-equity ratio of 0.09.

Glaukos (NYSE:GKOS – Get Free Report) last released its quarterly earnings data on Wednesday, October 28th. The medical instruments supplier reported $0.47 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.10) by $0.57. The firm had revenue of $211.03 million during the quarter, compared to analyst estimates of $168.04 million. Glaukos had a negative return on equity of 0.97% and a negative net margin of 24.60%. The business’s revenue for the quarter was up 58.0% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.16) earnings per share. Analysts forecast that Glaukos Corporation will post 0.50 earnings per share for the current year.

Institutional Trading of Glaukos

Large investors have recently made changes to their positions in the business. Allworth Financial LP acquired a new stake in shares of Glaukos in the second quarter valued at $28,000. Fulcrum Asset Management LLP increased its position in Glaukos by 91.7% in the 3rd quarter. Fulcrum Asset Management LLP now owns 184 shares of the medical instruments supplier’s stock valued at $29,000 after acquiring an additional 88 shares in the last quarter. CoreCap Advisors LLC bought a new position in shares of Glaukos in the third quarter worth about $33,000. Fortitude Family Office LLC bought a new position in shares of Glaukos in the third quarter worth about $36,000. Finally, Parallel Advisors LLC raised its stake in shares of Glaukos by 159.2% in the first quarter. Parallel Advisors LLC now owns 368 shares of the medical instruments supplier’s stock worth $40,000 after acquiring an additional 226 shares during the last quarter. Institutional investors own 99.04% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on GKOS shares. BTIG Research increased their target price on shares of Glaukos from $234.00 to $252.00 and gave the stock a “buy” rating in a research report on Monday. Wall Street Zen upgraded shares of Glaukos from a “buy” rating to a “strong-buy” rating in a research report on Saturday, November 7th. Mizuho set a $225.00 price target on shares of Glaukos in a research report on Thursday, October 29th. Truist Financial upped their price objective on shares of Glaukos from $215.00 to $255.00 and gave the stock a “buy” rating in a research note on Thursday, October 29th. Finally, Stifel Nicolaus upped their price objective on shares of Glaukos from $190.00 to $225.00 and gave the stock a “buy” rating in a research note on Thursday, October 29th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $218.00.

Check Out Our Latest Report on Glaukos

More Glaukos News

Here’s some of the latest news about GKOS:

  • Positive Sentiment: Zacks Research lifted its FY2026 EPS estimate to $0.42 from a forecasted loss of $0.43, and its FY2027 estimate to $1.24 from $0.45. It also raised its FY2028 forecast to $2.24 from $1.70 and increased estimates for multiple quarters. The revisions suggest improved expectations for earnings growth, although they come from one research firm. Glaukos analyst estimates
  • Negative Sentiment: COO Joseph Gilliam sold 861 shares for about $215,000 at $250 per share, reducing his stake by 1.19%. The sale may weigh modestly on sentiment, but he still owned 71,602 shares after the transaction. Insider sale report

Glaukos Company Profile

(Get Free Report)

Glaukos Corporation is an ophthalmic medical technology company that develops and commercializes treatments for glaucoma and other eye disorders. Its portfolio includes minimally invasive glaucoma surgery (MIGS) devices, such as the iStent family, and iDose TR, an implant designed to deliver glaucoma medication inside the eye over an extended period. The company also offers products for corneal disorders, including technology used in corneal cross-linking procedures to treat keratoconus and other conditions that weaken the cornea.

Featured Articles

Insider Buying and Selling by Quarter for Glaukos (NYSE:GKOS)

Receive News & Ratings for Glaukos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos and related companies with MarketBeat.com's FREE daily email newsletter.